-
Active Trials
-
Phase 3
-
Phase 2
-
Phase 1
-
Results Pending
📊
Pipeline Summary
Expected Approvals
FDA Decisions 2 upcoming PDUFA dates
Iberdomide + daratumumab/dexamethasone Relapsed or refractory multiple myeloma NDA
Camzyos (mavacamten) Symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adolescents (12 to <18 years) sNDA
Clinical Trials
Loading...